Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,457.00    6.00 (0.41%)
Bid:
1,464.00
Ask:
1,466.00
Spread: 2.00 (0.137%)
Market Cap: £3.08b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Block listing Interim Review

4 Oct 2021 09:55

RNS Number : 9028N
Hikma Pharmaceuticals Plc
04 October 2021
 

Hikma Pharmaceuticals PLC

 

 

Block Listing Six Monthly Return

 

Date: 4 October 2021

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2004 Stock Option Plan ("SOP")

 

Period of return

From: 1 April 2021

To:

30 September 2021

Balance of unallotted securities under scheme(s) from previous return:

SOP: 792,700 Ordinary Shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

SOP: 0 Ordinary Shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

SOP: 0 Ordinary Shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

SOP: 792,700 Ordinary Shares of 10 pence

 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

 

 

Block Listing Six Monthly Return

 

Date: 4 October 2021

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan ("LTIP")

Period of return

From: 1 April 2021

To:

30 September 2021

Balance of unallotted securities under scheme(s) from previous return:

LTIP: 57,502 Ordinary Shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

LTIP: 0 Ordinary Shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

LTIP: 0 Ordinary Shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

LTIP: 57,502 Ordinary Shares of 10 pence

 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

 

Block Listing Six Monthly Return

 

Date: 4 October 2021

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2009 Management Incentive Plan ("2009 MIP")

Period of return

From: 1 April 2021

To:

30 September 2021

Balance of unallotted securities under scheme(s) from previous return:

2009 MIP: 136,182 Ordinary Shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

2009 MIP: 0 Ordinary Shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

2009 MIP: 136,182 Ordinary Shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

2009 MIP: 0 Ordinary Shares of 10 pence

 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

 

Block Listing Six Monthly Return

 

Date: 4 October 2021

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2018 Management Incentive Plan ("2018 MIP")

Period of return

From: 1 April 2021

To:

30 September 2021

Balance of unallotted securities under scheme(s) from previous return:

2018 MIP: 1,000,000 Ordinary Shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

2018 MIP: 0 Ordinary Shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

2018 MIP: 226,506 Ordinary Shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

2018 MIP: 773,494 Ordinary Shares of 10 pence

 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

 

Block Listing Six Monthly Return

 

Date: 4 October 2021

 

Name of applicant:

Hikma Pharmaceuticals PLC

Name of scheme:

Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan ("EIP")

Period of return

From: 1 April 2021

To:

30 September 2021

Balance of unallotted securities under scheme(s) from previous return:

EIP: 1,239,967 Ordinary Shares of 10 pence

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

EIP: 350,000 Ordinary Shares of 10 pence

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

EIP: 340,434 Ordinary Shares of 10 pence

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

EIP: 1,249,533 Ordinary Shares of 10 pence

 

Name of contact:

Peter Speirs

Telephone number of contact:

0207 399 2772

 

LEI: 549300BNS685UXH4JI75

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRUPGCAUUPGURC
Date   Source Headline
7th Feb 20087:00 amRNSVoting Rights and Capital
21st Jan 20082:58 pmRNSNotification of transaction
17th Jan 20082:02 pmRNSResult of Equity Issue
17th Jan 20087:01 amRNSTrading Update
17th Jan 20087:01 amRNSIssue of Equity
8th Jan 20083:46 pmRNSDirector/PDMR Shareholding
7th Jan 20081:17 pmRNSDirector/PDMR Shareholding
2nd Jan 200812:48 pmRNSDirector/PDMR Shareholding
2nd Jan 20089:49 amRNSDirector/PDMR Shareholding
17th Dec 20072:05 pmRNSDirector/PDMR Shareholding
14th Dec 20077:01 amRNSPre-close trading statement
10th Dec 20071:19 pmRNSHikma acquires APM
30th Nov 200711:18 amRNSVoting Rights and Capital
21st Nov 20073:56 pmRNSUpdate on Lisinopril Contract
31st Oct 20074:51 pmRNSLegal and General DTR Announc
15th Oct 20075:06 pmRNSDirector / PDMR Shareholding
8th Oct 20077:01 amRNSConditional cash offer
8th Oct 20077:00 amRNSBlock Listing of Shares
5th Oct 20077:00 amRNSBlocklisting - 6 Month Review
19th Sep 20074:22 pmRNSOption Exercise
14th Sep 20072:58 pmRNSDirector/PDMR Shareholding
11th Sep 20074:28 pmRNSNotification of transaction
7th Sep 20072:20 pmRNSNotification of transaction
5th Sep 20077:02 amRNSInterim Results 2007
9th Aug 20077:00 amRNSHikma enters Egyptian market
27th Jun 20077:01 amRNSPre-close trading statement
6th Jun 20071:45 pmRNSAGM Statement
6th Jun 20077:00 amRNSAGM Statement
14th May 20074:42 pmRNSAnnual information update
23rd Apr 20071:33 pmRNSHikma appoints new CEO
20th Apr 20072:57 pmRNSHikma acquires Thymoorgan
5th Apr 20079:50 amRNSBlock Listing 6-month review
5th Apr 20079:35 amRNSNotification of transaction
3rd Apr 20071:14 pmRNSLTIP awards
3rd Apr 200711:59 amRNSNotification of transaction
3rd Apr 200711:59 amRNSNotification of transaction
3rd Apr 200711:59 amRNSNotification of transaction
3rd Apr 200711:59 amRNSNotification of transaction
3rd Apr 200710:12 amRNSNotification of transaction
2nd Apr 200712:00 pmRNSNotification of transaction
2nd Apr 200710:27 amRNSNotification of transaction
2nd Apr 200710:26 amRNSNotification of transaction
2nd Apr 200710:26 amRNSVoting rights and capital
23rd Mar 200710:36 amRNSInterest in shares
22nd Mar 20077:03 amRNSFinal Results
26th Jan 200710:49 amRNSCompletion of Acquisition
22nd Jan 20077:02 amRNSHikma enters oncology market
18th Jan 20077:01 amRNSPre-close Trading Statement
21st Dec 20061:11 pmRNSVoting rights and capital
12th Dec 20062:08 pmRNSNew board appointment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.